

when  $G_5 = C(CHOJ_{15})$  and  $G_6 = CHCH_2(OJ_{19})$ ,  $J_{15}$  and  $J_{19}$  optionally are bonds from the oxygen atoms of  $G_5$  and  $G_6$ , respectively, to a carbon atom of an acetal, ketal or orthoester group  $G_{14}$ ; wherein  $G_{14} = Q_1(T_1)(T_2)$ ; or

when  $G_4 = CH(OJ_1)$  and  $G_6 = CH(CH_2OJ_{19})$  or  $CH(OJ_{19})$ ,  $J_1$  and  $J_{19}$  are optionally bonds from the oxygen atoms of  $G_4$  and  $G_6$ , respectively, to a carbon atom of an acetal, ketal or orthoester group  $G_{12}$ ;

wherein  $G_{12} = Q_1(T_1)(T_2)$ ;

wherein  $Q_1$  is a carbon atom; and

$T_1 = H, CF_3$ , alkyl, cycloalkyl, arylalkyl or aryl;

$T_2 = H, OT_3, CF_3$ , alkyl, cycloalkyl, arylalkyl, aryl or heterocycle of 5 to 7 members;

$T_3 =$  alkyl, cycloalkyl, arylalkyl or aryl; or

$T_1$  and  $T_2$ , when taken together, form a carbocyclic ring of 5 or 6 members, with or without unsaturation and with or without substitution; or

$Q_1(T_1)(T_2)$  is taken together to form a carbonyl, such that a cyclic carbonate is formed.

2. (Currently Amended) The method according to Claim 1, wherein:

$X_1 = O, NR, S$ ; or

$X_1$  represents a bond from the pyrimidine ring to  $R_4$ ;

$X_2 = H, F, Cl, Br, I, CF_3$ , alkyl, cycloalkyl, arylalkyl, aryl, arylalkenyl, arylalkynyl,  $C(O)OR_{17}$ ,  $C(O)NR_{16}R_{18}$  or heterocycle of 5 to 7 members;

$X_3 = H, CN, C(O)OR_{33}$ ;

$R = H$ , alkyl, cycloalkyl, arylalkyl, aryl;

$Y_1 = O$ ; or

$Y_1$  represents a bond from the point of ring attachment to  $M_1$ ;

$Y_2 = O$ ; or

$Y_2$  represents a bond from the point of ring attachment to  $M_2$ ;

$M_3 =$  alkyl, cycloalkyl, arylalkyl, or aryl;

$M_4 =$  alkyl, cycloalkyl, arylalkyl or aryl;

$A_1 = H$ , alkyl, cycloalkyl, arylalkyl or aryl;

$A_2 = H$ , alkyl, cycloalkyl, arylalkyl, aryl or heterocycle of 5 to 7 members; or

~~where A<sub>1</sub> and A<sub>2</sub>, when taken together, form a carbocyclic ring of 5 or 6 members, with or without unsaturation, and with or without substitution; or~~  
~~M<sub>1</sub>Q(A<sub>1</sub>)(A<sub>2</sub>)M<sub>2</sub> is taken together to form a carbonyl bonded to Y<sub>1</sub> and Y<sub>2</sub>, such that a cyclic carbonate is formed;~~  
Z = O, CH<sub>2</sub>, CF<sub>2</sub>, or CCl<sub>2</sub>;  
G<sub>2</sub> = CH, C(CH<sub>2</sub>OJ<sub>3</sub>), or C(CO<sub>2</sub>J<sub>4</sub>);  
J<sub>3</sub> = alkyl or C(O)J<sub>2</sub>;  
J<sub>4</sub> = alkyl;  
J<sub>5</sub> = H, alkyl or C(O)J<sub>6</sub>;  
J<sub>7</sub> = H, or alkyl;  
J<sub>9</sub> = H, alkyl or C(O)J<sub>10</sub>;  
J<sub>13</sub> = H, alkyl, or C(O)J<sub>14</sub>;  
J<sub>15</sub> = H, alkyl, or C(O)J<sub>16</sub>;  
J<sub>17</sub> = H, alkyl, or C(O)J<sub>18</sub>;  
J<sub>21</sub> = H, alkyl, C(O)J<sub>22</sub> or heterocyclic ring of 5 to 7 members;  
T<sub>1</sub> = H, alkyl, or arylalkyl;  
T<sub>2</sub> = H, alkyl, arylalkyl, or heterocycle of 5 to 7 members; or  
T<sub>1</sub> and T<sub>2</sub>, when taken together, form a carbocyclic ring of 5 or 6 members, with or without unsaturation and with or without substitution; or  
Q<sub>1</sub>(T<sub>1</sub>)(T<sub>2</sub>) is taken together to form a carbonyl, such that a cyclic carbonate is formed.

3. (Currently Amended) The method according to Claim 2, wherein:

X<sub>1</sub> = O, NR, S;  
X<sub>2</sub> = H, F, Cl, Br, I, CF<sub>3</sub>, alkyl, arylalkyl, aryl, arylalkenyl, arylalkynyl, or heterocycle of 5 to 7 members;  
X<sub>3</sub> = H;  
R = H, alkyl, cycloalkyl, arylalkyl, aryl;  
R<sub>4</sub> = H, alkyl, cycloalkyl, arylalkyl, aryl, or C(O)R<sub>5</sub>;  
R<sub>5</sub> is H, alkyl, cycloalkyl, arylalkyl, aryl or heterocyclic ring of 5 to 7 members;

$E_1$  and  $E_2$  are H;

$Y_1 = O$ ;

$Y_2 = O$ ;

$M_1$  and  $M_2$  are independently H, alkyl, cycloalkyl, arylalkyl, aryl,  $C(O)M_3$ ;

$M_3 =$  alkyl, cycloalkyl, arylalkyl, or aryl;

$A_1 =$  H, alkyl, cycloalkyl, arylalkyl or aryl;

$A_2 =$  H, alkyl, cycloalkyl, arylalkyl, or aryl;

$Z = O, CH_2, CF_2$ , or  $CCl_2$ ;

$G_1 = O$  or S;

$G_2 = CH$ ;

$G_3 = CH_2, CH(OJ_5)$  or  $CH(NJ_6J_7)$   $CH(OH)$ , or  $CH(NHJ_7)$ ;

$G_4 = CH_2, CH(OJ_9)$ , or  $CH(NJ_{11}J_{13})$   $CH(OH)$ , or  $CH(NHJ_{13})$ ;

$G_5 = CH_2, CH(OJ_{15})$ , or  $CH(NJ_{16}J_{17})$ ;  $CH(OH)$ , or  $CH(NHJ_{17})$ ;

$G_6 = CH_2, CH(CH_3), CH(OJ_{19}), CH(CH_2OJ_{19}), CH(CH_2(NJ_{21}J_{23}))$ , or

$CH(CO_2J_{21})$ , with the provision that when  $G_1 = O$  or S, then  $G_6$  does not equal  $CH(OH)$ ; and

the number of hydrogen atoms bonded to the  $G_1$ - $G_6$  ring atoms is limited to a maximum of 8;

also with the provision that the number of nitrogen atoms bonded to the  $G_1$ - $G_6$  ring atoms in

Formula I is limited to a maximum of 2;

$J_6, J_{11}$ , and  $J_{16}$  are independently H, alkyl, arylalkyl, or aryl;

$J_5 =$  H, alkyl or  $C(O)J_6$ ;

$J_7 =$  H, or alkyl;

$J_9 =$  H, alkyl or  $C(O)J_{10}$ ;

$J_{13} =$  H, alkyl, or  $C(O)J_{14}$ ;

$J_{15} =$  H, alkyl, or  $C(O)J_{16}$ ;

$J_{17} =$  H, alkyl, or  $C(O)J_{18}$ ;

$J_{19} =$  H, alkyl, or  $C(O)J_{20}$ ;


$J_{21} =$  H, alkyl, or  $C(O)J_{22}$ ; and

$J_{23} =$  H, alkyl, or  $C(O)J_{24}$ .

4. (Original) The method according to Claim 1, wherein said method further comprises the step of measuring the intraocular pressure of said subject before administering the composition.
5. (Original) The method according to Claim 1, further comprising the step of measuring the intraocular pressure of said subject after administering the composition.
6. (Original) The method according to Claim 1, wherein administering said pharmaceutical composition to said subject is to treat ocular hypertension.
7. (Original) The method according to Claim 6, wherein administering said pharmaceutical composition to said subject is to treat glaucoma.
8. (Original) The method according Claim 1, wherein said pharmaceutical composition is co-administered to said subject with other therapeutic agent or adjuvant therapy commonly used to reduce intraocular pressure.
9. (Original) The method according to Claim 1, wherein said pharmaceutical composition is administered topically to said subject.
10. (Original) The method according to Claim 1, wherein said pharmaceutical composition is administered via subconjunctival, subcleral, or intravitreal injection to said subject.

11. (Withdrawn) A compound according to Formula IA:

**Formula IA**




wherein:

R<sub>4</sub> = alkyl, cycloalkyl, arylalkyl, aryl, heterocyclic ring of 5 to 7 members, C(O)R<sub>5</sub>,  
C(O)OR<sub>6</sub> or C(O)NR<sub>5</sub>R<sub>7</sub>;

X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, R, R<sub>1</sub>–R<sub>3</sub>, R<sub>5</sub>–R<sub>35</sub>, E, E<sub>1</sub>, E<sub>2</sub>, Y<sub>1</sub>, Y<sub>2</sub>, M<sub>1</sub>–M<sub>5</sub>, A<sub>1</sub>–A<sub>3</sub>, Z, Z<sub>1</sub>–Z<sub>3</sub>, G<sub>1</sub>–G<sub>6</sub>, J<sub>1</sub>–J<sub>24</sub>, G<sub>1</sub>–G<sub>12</sub>,  
T<sub>1</sub>–T<sub>3</sub> are the same as those described in Formula I in Claim 1.

12. (Withdrawn) A compound of Formula IB:

Formula IB



wherein:


$X_2$ ,  $X_3$ ,  $R$ ,  $R_1$ – $R_3$ ,  $R_5$ – $R_{35}$ ,  $E$ ,  $E_1$ ,  $E_2$ ,  $Y_1$ ,  $Y_2$ ,  $M_1$ – $M_5$ ,  $A_1$ – $A_3$ ,  $Z$ ,  $Z_1$ – $Z_3$ ,  $G_1$ – $G_6$ ,  $J_1$ – $J_{24}$ ,  $G_1$ – $G_{12}$ ,  $T_1$ – $T_3$  are the same as those described in Formula I in Claim 1;

provided that when  $E = Y_1 = Y_2 = Z = Z_1 = Z_2 = G_1 = O$ ,  $E_1 = E_2 = H$ ,

$G_2 = CH$ ,  $G_3 = CH(OJ_5)$ ,  $G_4 = CH(OJ_9)$ ,  $G_5 = CH(OJ_{15})$  and  $G_6 = CH(CH_2OJ_{19})$ , then at least one of  $X_2$ ,  $X_3$ ,  $M_1$ ,  $M_2$ ,  $J_5$ ,  $J_9$ ,  $J_{15}$ , or  $J_{19}$  is not equal to H.

13. (Withdrawn) A compound of Formula IC:

Formula IC:



wherein

$X_2$ ,  $X_3$ ,  $R$ ,  $R_1$ – $R_3$ ,  $R_5$ – $R_{35}$ ,  $E$ ,  $E_1$ ,  $E_2$ ,  $Y_1$ ,  $Y_2$ ,  $M_1$ – $M_5$ ,  $A_1$ – $A_3$ ,  $Z$ ,  $Z_1$ – $Z_3$ ,  $G_1$ – $G_6$ ,  $J_1$ – $J_{24}$ ,  $G_1$ – $G_{12}$ ,  $T_1$ – $T_3$  are the same as those described in Formula I in Claim 1;

provided that when  $E = Y_1 = Y_2 = Z = Z_1 = Z_2 = O$ ,  $G_1 = O$  or  $CH(OH)$ ,  $E_1 = E_2 = H$ ,  $G_2 = CH$ ,  $G_3 = CH(OJ_5)$ ,  $G_4 = CH(OJ_9)$ ,  $G_5 = CH(OJ_{15})$  and  $G_6 = CH(CH_2OJ_{19})$ , then at least one of  $X_2$ ,  $X_3$ ,  $M_1$ ,  $M_2$ ,  $J_5$ ,  $J_9$ ,  $J_{15}$ , or  $J_{19}$  is not equal to H;

further provided that when  $X_2 = H$  or  $CH_2OH$ ,  $E = Y_1 = Z = Z_1 = Z_2 = G_1 = O$ ,  $Y_2 = \text{bond to } M_2 \text{ from ring}$ ,  $E_1 = E_2 = M_2 = H$ ,  $G_2 = CH$ ,  $G_3 = CH(OJ_5)$  and  $G_4 = CH(OJ_9)$ ,  $G_5 = CH(OJ_{15})$ ,  $G_6 = CH(CH_2OJ_{19})$ , then at least one of  $X_3$ ,  $M_1$ ,  $J_5$ ,  $J_9$ ,  $J_{15}$ , or  $J_{19}$  is not equal to H;

further provided that when  $E = Y_1 = Y_2 = Z = Z_1 = Z_2 = G_1 = O$ ,  $E_1 = E_2 = H$ ,  $G_2 = CH$ ,  $G_3 = CH(OJ_5)$ ,  $G_4 = CH_2$ ,  $G_5 = CH(OJ_{15})$ ,  $G_6 = CH(CH_3)$ , then at least one of  $X_2$ ,  $X_3$ ,  $M_1$ ,  $M_2$ ,  $J_5$ , or  $J_{15}$  is not equal to H;

further provided that when  $E = Y_1 = Y_2 = Z = Z_1 = Z_2 = G_1 = O$ ,  $E_1 = E_2 = H$ ,  $G_2 = CH$ ,  $G_3 = CH_2$  or  $CH(NH_2)$ ,  $G_4 = CH(OJ_9)$ ,  $G_5 = CH(OJ_{15})$ ,  $G_6 = CH(CH_3)$ , then at least one of  $X_2$ ,  $X_3$ ,  $M_1$ ,  $M_2$ ,  $J_9$ , or  $J_{15}$  is not equal to H;

further provided that when  $E = Y_1 = Y_2 = Z = Z_1 = Z_2 = G_1 = O$ ,  $E_1 = E_2 = H$ ,  $G_2 = CH$ ,  $G_3 = CH(NH_2)$ ,  $G_4 = CH(OJ_9)$ ,  $G_5 = CH(OJ_{15})$ ,  $G_6 = CH(CH_2(NH_2))$ , then at least one of  $X_2$ ,  $X_3$ ,  $M_1$ ,  $M_2$ ,  $J_9$ , or  $J_{15}$  is not equal to H;


further provided that when  $E = Y_1 = Y_2 = Z = Z_1 = Z_2 = G_1 = O$ ,  $E_1 = E_2 = H$ ,  $G_2 = CH$ ,  $G_3 = CH(OH)$ ,  $G_4 = CH_2$ ,  $G_6 = CH(CH_3)$ , then  $G_5$  is not equal to CHF;

further provided that when  $E = Y_1 = Y_2 = Z = Z_1 = Z_2 = G_1 = O$ ,  $E_1 = E_2 = X_2 = X_3 = M_1 = M_2 = H$ ,  $G_2 = CH$ ,  $G_3 = CH(OH)$ ,  $G_4 = CH(OH)$ ,  $G_5 = CH(OH)$ , then  $G_6$  is not  $CH(CH_3)$  or  $CH(CHF_2)$ ;

further provided that when  $E = Y_1 = Y_2 = Z = Z_1 = Z_2 = G_1 = O$ ,  $E_1 = E_2 = H$ ,  $G_2 = CH$ ,  $G_3 = CH(OH)$ ,  $G_5 = CH(OH)$ ,  $G_6 = CH(CH_2OH)$  then  $G_4$  is not CHF.

14. (Withdrawn) A compound of Formula ID:

**Formula ID**




wherein:

X<sub>3</sub> = CN, OR<sub>19</sub>, SR<sub>19</sub>, NR<sub>23</sub>R<sub>28</sub>, CF<sub>3</sub>, alkyl, cycloalkyl, C(O)R<sub>32</sub>, C(O)OR<sub>33</sub>, C(O)NR<sub>34</sub>R<sub>35</sub>, arylalkyl, aryl, arylalkenyl, arylalkynyl, or a heterocycle of 5 to 7 members;

X<sub>2</sub>, X<sub>3</sub>, E, E<sub>1</sub>, E<sub>2</sub>, Y<sub>1</sub>, Y<sub>2</sub>, M<sub>1</sub>, M<sub>2</sub>, Z, Z<sub>1</sub>, Z<sub>2</sub>, and G<sub>1</sub>–G<sub>6</sub> are the same as those described in Formula I in Claim 1.

15. (Withdrawn) A compound of Formula IE:

FORMULA IE




wherein:

X<sub>2</sub>, X<sub>3</sub>, E<sub>1</sub>, E<sub>2</sub>, Y<sub>1</sub>, Y<sub>2</sub>, M<sub>1</sub>, M<sub>2</sub>, Z, Z<sub>1</sub>, Z<sub>2</sub>, G<sub>2</sub>-G<sub>6</sub> and J<sub>1</sub> are the same as those described in Formula I in Claim 1.

16. (Withdrawn) A compound of Formula IF:

Formula IF




wherein:

X<sub>2</sub>, X<sub>3</sub>, E<sub>1</sub>, E<sub>2</sub>, Y<sub>2</sub>, M<sub>2</sub>, Z, Z<sub>1</sub>, Z<sub>2</sub>, G<sub>2</sub>–G<sub>6</sub> are the same as those described in Formula I;

Provided that when X<sub>2</sub> = CH<sub>3</sub>, X<sub>3</sub> = E<sub>1</sub> = E<sub>2</sub> = M<sub>2</sub> = H, E = Y<sub>2</sub> = Z = Z<sub>1</sub> = Z<sub>2</sub> = G<sub>1</sub> = O, G<sub>2</sub> = CH, G<sub>3</sub> = G<sub>4</sub> = G<sub>5</sub> = CH(OH), then G<sub>6</sub> is not CH(CH<sub>3</sub>) or CH(CH<sub>3</sub>) or CH(CH<sub>2</sub>OH).

Formula IG




wherein:

X<sub>2</sub> is aryl, arylalkyl, arylalkenyl, arylalkynyl, C<sub>2</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, alkynyl, cycloalkyl, or C<sub>3</sub>-C<sub>8</sub> branched alkyl, and none of the alkyl groups in X<sub>2</sub> are substituted with an amine or an amide on the chain, or contain a nitrogen hetero atom;

X<sub>3</sub>, E<sub>1</sub>, E<sub>2</sub>, M<sub>1</sub>, M<sub>2</sub>, Y<sub>1</sub>, Y<sub>2</sub>, Z, Z<sub>1</sub>, Z<sub>2</sub>, G<sub>1</sub>-G<sub>6</sub> are the same as those described in Formula I in Claim 1.

17. (Withdrawn) A compound of Formula IH:

Formula IH




wherein:

$X_2$ ,  $X_3$ , E,  $E_1$ ,  $E_2$ ,  $M_1$ ,  $M_2$ ,  $Y_1$ ,  $Y_2$ , Z,  $Z_1$ ,  $Z_2$ ,  $G_2$ - $G_5$  and  $J_{21}$  are the same as those described in Formula I in Claim 1;

provided that when  $X_2 = X_3 = E_1 = E_2 = M_1 = M_2 = H$ ,  $E = Y_1 = Y_2 = Z = Z_1 = Z_2 = O$ ,  $G_2 = CH$ ,  $G_3 = G_4 = G_5 = CH(OH)$ , then  $J_{21}$  is not H or  $CH_3$ .

18. (Withdrawn) A compound of Formula II:

Formula II



wherein:

$X_2$ ,  $X_3$ , E,  $E_1$ ,  $E_2$ ,  $A_1$ ,  $A_2$ , Z,  $Z_1$ ,  $Z_2$  and  $G_2$ - $G_6$  are the same as those described in Formula I in Claim 1;

provided that when  $X_2 = X_3 = E_1 = E_2 = H$ , and  $E = Z_1 = Z_2 = G_1 = O$ , and  $A_1 = A_2 = CH_3$ , then Z is not equal to  $CH_2$  or  $CF_2$ ;

further provided that when  $X_2 = X_3 = E_1 = E_2 = H$ , and  $E = Z = Z_1 = Z_2 = G_1 = O$ , and  $A_1$  and  $A_2$  are taken together to form an unsaturated 6-membered ring, then  $G_6$  is not  $CH(CH_2OH)$ .

19. (New) The method according to Claim 1, wherein said compound is uridine 5'-diphospho- $\alpha$ -glucose.

20. (New) The method according to Claim 1, wherein said compound is uridine 5'-diphospho- $\alpha$ -galactose.

21. (New) The method according to Claim 1, wherein said compound is uridine 5'-diphospho-N-acetylglucosamine.